Recruiting

Radiofrequency AblationRadio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry

Sponsor:

Weill Medical College of Cornell University

Code:

NCT01439698

Conditions

Cholangiocarcinoma

Pancreatic Cancer

Bile Duct Cancer

Biliary Stricture

Bile Duct Obstruction

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Radio Frequency ablation Probe

Study Details

Brief summary:

The objective of this protocol is to establish a multicenter registry to evaluate the impact of radiofrequency ablation in the management of patients with pancreatico-biliary disorders including malignancies.

Conditions

Cholangiocarcinoma

Pancreatic Cancer

Bile Duct Cancer

Biliary Stricture

Bile Duct Obstruction

Study ID

NCT01439698

Start date

Sep, 2011

Status verified date

Feb, 2017

Completion date

Dec 30, 2018

Anticipated

Primary completion date

Dec 1, 2018

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Patients who have undergone RFA for pancreaticobiliary disorders
Above 18 years of age

Exclusion Criteria:

Patients who have not undergone RFA
Below 18 years of age

Study Design

Enrollment

200 participants

Anticipated

Interventions and Outcome Measures

Arms

RFA for Pancreatico-biliary disorders

Subjects who will receive radiofrequency ablation for pancreatico-biliary disorders, including malignancies.

Interventions

Radio Frequency ablation Probe

Any probe that can conduct radiofrequency ablation within biliary ducts.

Primary outcome measure

Change from Baseline in Bile Duct Stricture Diameter. [ Time Frame: 4 years ]
Number of Participants with Adverse Events [ Time Frame: 4 years ]

Central Contacts and Locations

Central contacts

Michel Kahaleh, MD

646-962-4000 mik9071@med.cornell.edu

Monica R Gaidhane, MD, MPH

646-962-4796 mog2012@med.cornell.edu

Locations

Massachusetts General Hospital

Recruiting

Boston, Massachusetts, United States, 02114

Contacts

William R Brugge, MD

617-724-0578 WBRUGGE@PARTNERS.ORG

Principal Investigator:

William R Brugge, MD

Weill Cornell Medical College

Recruiting

New York, New York, United States, 10021

Contacts

Michel Kahaleh, MD

646-962-4000 mik9071@med.cornell.edu

Monica R Gaidhane, MD, MPH

646 962 4797 mog2012@med.cornell.edu

Principal Investigator:

Michel Kahaleh, MD

More Information

Sponsor

Weill Medical College of Cornell University

Last update posted

Feb 20, 2017

Last verified

Feb, 2017

Keywords

Cholangiocarcinoma
Pancreatic Cancer
Bile Duct Cancer
Biliary Stricture
Bile duct obstruction
ENDOHPB
Radio Frequency Ablation
RFA
ERCP
Endoscopic Retrograde Cholangiopancreatography
Registry
Multicenter

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Weill Medical College of Cornell University on 2017-02-20.